Nimbus Therapeutics

CAMBRIDGE, MA

Nimbus Therapeutics is applying advances in computer-based drug discovery to develop new medicines against important drug targets and thereby unlock fundamental biological pathways. Nimbus has established a first-of-its-kind partnership with Schrödinger, the leader in computational drug discovery, to gain privileged access to cutting-edge technology and exclusive rights to key targets. Nimbus has identified selective, potent, and differentiated compounds for two disease targets, ACC and IRAK4, that are pivotal in the areas of immunology, obesity, and oncology.

Other Investors include Atlas Ventures, SR One, Gates Ventures, Pfizer Venture Investments, and Lightstone Ventures.